dactinomycin has been researched along with Respiratory Tract Infections in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisher, JH; Kim, KS; Kuzmenko, A; McCormack, FX; Schaffer, L; Wan, S; Weiss, A; Wu, H | 1 |
| HILL, RB; RIFKIND, D; ROWLANDS, DT | 1 |
| Mowbray, J | 1 |
| Bieber, CP; Clark, DA; Griepp, RB; Remington, JS; Shumway, NE; Stinson, EB | 1 |
| Abe, T; Fujii, R; Meguro, H; Nakazawa, S; Niinou, K; Sato, H; Sunakawa, K; Tajima, T; Terashima, I; Yokota, T | 1 |
| Hayashi, R; Iizawa, Y; Imada, A; Iwahi, T; Okonogi, K; Yamazaki, T | 1 |
1 trial(s) available for dactinomycin and Respiratory Tract Infections
| Article | Year |
|---|---|
[Pharmacokinetic and clinical studies with cefozopran in the pediatric field. Pediatric Study Group of Cefozopran].
Topics: Adolescent; Bacteria; Bacterial Infections; Cefozopran; Cephalosporins; Child; Child, Preschool; Diarrhea; Drug Eruptions; Female; Half-Life; Humans; Infant; Japan; Male; Meningitis, Bacterial; Respiratory Tract Infections; Urinary Tract Infections | 1994 |
5 other study(ies) available for dactinomycin and Respiratory Tract Infections
| Article | Year |
|---|---|
Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability.
Topics: Animals; Bacterial Outer Membrane Proteins; Bronchoalveolar Lavage Fluid; Cell Division; Cell Membrane Permeability; Collectins; Dactinomycin; Escherichia coli; Escherichia coli Infections; Fluorescent Dyes; Genetic Predisposition to Disease; Gram-Negative Bacteria; Humans; Mice; Mice, Inbred C3H; Mice, Knockout; Microbial Sensitivity Tests; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Rats; Rats, Sprague-Dawley; Respiratory Tract Infections | 2003 |
INFECTIOUS PULMONARY DISEASE IN PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY FOR ORGAN TRANSPLANTATION.
Topics: Animals; Antimetabolites; Aspergillosis; Azathioprine; Candidiasis; Cytomegalovirus Infections; Dactinomycin; Haplorhini; Humans; Immune Tolerance; Immunosuppression Therapy; Kidney Transplantation; Liver; Lung Diseases; Lung Diseases, Fungal; Metabolism; Nocardia Infections; Pathology; Plasma Cells; Pneumonia; Pneumonia, Pneumocystis; Prednisone; Pseudomonas Infections; Respiratory Tract Infections; Spleen; Transplantation Immunology; Transplantation, Heterologous; Transplantation, Homologous | 1964 |
Platelet thrombi in rejection episodes.
Topics: Antibody Formation; Azathioprine; Blood Coagulation; Blood Platelets; Chromium Isotopes; Dactinomycin; Humans; Hydrocortisone; Kidney Transplantation; Mercaptopurine; Respiratory Tract Infections; Transplantation Immunology; Transplantation, Homologous | 1969 |
Infectious complications after cardiac transplantation in man.
Topics: Adult; Amphotericin B; Antilymphocyte Serum; Azathioprine; Dactinomycin; Female; Heart Transplantation; Humans; Infections; Male; Middle Aged; Mycoses; Nystatin; Prednisone; Propylene Glycols; Protozoan Infections; Respiratory Tract Infections; Sepsis; Staphylococcal Infections; Transplantation Immunology; Transplantation, Homologous; Urinary Tract Infections; Virus Diseases | 1971 |
Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice.
Topics: Animals; Bacterial Infections; Cefozopran; Cephalosporins; Female; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Muscular Diseases; Pseudomonas Infections; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus aureus; Urinary Tract Infections | 1993 |